Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <i>In vitro</i> and <i>In vivo</i> - Concepedia

Concepedia

Publication | Closed Access

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <i>In vitro</i> and <i>In vivo</i>

209

Citations

30

References

2010

Year

Zev A. Wainberg, Adrian Anghel, Amrita Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, Richard S. Finn

Clinical Cancer Research

Abstract

Together, these data suggest that lapatinib has activity in HER2-amplified upper gastrointestinal cancer and supports the ongoing clinical investigation of lapatinib in patients with HER2-amplified disease.

References

	Year	Citations

Page 1